US Patent

US10654866 — Selective estrogen receptor degraders

Method of Use · Assigned to Eli Lilly and Co · Expires 2039-07-11 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel selective estrogen receptor degraders and methods for their use, specifically compounds with certain chemical structures and their pharmaceutical compositions.

USPTO Abstract

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R 1 or R 2 is independently selected from Cl, F, âCF 3 , or âCH 3 , and the other is hydrogen, and methods for their use are provided.

Drugs covered by this patent

imlunestrant-tosylate (IMLUNESTRANT TOSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4278`	—	imlunestrant-tosylate

Patent Metadata

Patent number: US10654866
Jurisdiction: US
Classification: Method of Use
Expires: 2039-07-11
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.